What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 26637781)

Published in Hematology Am Soc Hematol Educ Program on December 05, 2015

Authors

J Evan Sadler1

Author Affiliations

1: Departments of Medicine and Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO.

Articles cited by this

Syndromes of thrombotic microangiopathy. N Engl J Med (2014) 5.41

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82

Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood (2009) 3.18

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol (2005) 2.86

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood (2008) 2.43

Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost (2015) 2.05

Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood (2005) 1.99

Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med (2008) 1.97

Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost (2008) 1.45

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One (2010) 1.33

ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32

Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion (2006) 1.28

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27

Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost (2009) 1.02

Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol (2003) 1.02

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99

Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog (2015) 0.98

Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura. J Clin Apher (2010) 0.94

Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke. Am J Hematol (2012) 0.91

Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion (2011) 0.90

Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion (2014) 0.89

Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost (2007) 0.88

Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant (2009) 0.87

Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med (2013) 0.84

An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost (2013) 0.84

Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One (2013) 0.84

Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology (2014) 0.84

Middle cerebral artery main stem thrombosis in two siblings with familial thrombotic thrombocytopenic purpura. Neurology (1998) 0.83

The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit Care (2013) 0.82

Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease. J Thromb Haemost (2015) 0.80

Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. Blood (2014) 0.80

Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology (2013) 0.79

Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr (2013) 0.79

A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher (2012) 0.79

Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. Am J Hematol (2014) 0.77

Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies. Intern Emerg Med (2012) 0.77

Experiences in a family with the Upshaw-Schulman syndrome over a 44-year period. Clin Appl Thromb Hemost (2013) 0.77

Neurological symptoms as the sole presentation of relapsed thrombotic thrombocytopenic purpura without microangiopathic haemolytic anaemia. Thromb Haemost (2014) 0.77

Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost (2015) 0.76